Denosumab is not associated with risk of malignancy: systematic review and meta-analysis of randomized controlled trials

Osteoporos Int. 2021 Oct;32(10):2131. doi: 10.1007/s00198-021-06033-y. Epub 2021 Aug 12.

D Rosenberg^{1

2}, T Avni^{3

4}, G Tsvetov^{4

5}, A Gafter-Gvili^{3

5}, T Diker-Cohen^{3

4

5}

¹ Medicine A, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel. roza.dana@gmail.com.
² Department of Rheumatology, Tel Aviv Sourasky Medical Center, 6 Weizmann St, 6423906, Tel Aviv, Israel. roza.dana@gmail.com.
³ Medicine A, Rabin Medical Center - Beilinson Hospital, Petah Tikva, Israel.
⁴ Diabetes and Metabolism, Rabin Medical Center - Beilinson Hospital, Institute of Endocrinology, Petah Tikva, Israel.
⁵ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

No abstract available

Publication types